Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label outpatient study of aripiprazole for schizophrenia or schizoaffective disorder
2004-001181-41Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in schizophrenia and schizoaffective disorder, sponsored by Bristol Myers Squibb. Primary endpoint: CGI-I score at Week 8. Started Oct 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2004-001181-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001181-41.